Showing results (71-80 of 86) with videos related to
Sort By:
Pageof 9
European Urology Oncology|December 17, 2023
A Phase 2 Study of Sitravatinib in Combination with Nivolumab in Patients with Advanced or Metastatic Urothelial CarcinomaPavlos Msaouel, Randy F Sweis, Manojkumar Bupathi, et al.Eclinicalmedicine|June 12, 2023
Metastatic renal cell carcinoma to the pancreas and other sites-a multicenter retrospective studyCassandra Duarte, Junxiao Hu, Benoit Beuselinck, et al.Urologic Oncology|November 28, 2022
A multicenter study assessing survival in patients with metastatic renal cell carcinoma receiving immune checkpoint inhibitor therapy with and without cytoreductive nephrectomyEvan E Gross, Mingjia Li, Ming Yin, et al.JAMA Oncology|October 21, 2021
Clinical Activity and Safety of Cabozantinib for Brain Metastases in Patients With Renal Cell CarcinomaLaure Hirsch, Nieves Martinez Chanza, Subrina Farah, et al.Journal of Immunology (Baltimore, Md. : 1950)|August 5, 2015
The Raf Kinase Inhibitor Sorafenib Inhibits JAK-STAT Signal Transduction in Human Immune CellsSara E Martin del Campo, Kala M Levine, Bethany L Mundy-Bosse, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|December 2, 2020
Circulating Tumor Cell Subtypes and T-cell Populations as Prognostic Biomarkers to Combination Immunotherapy in Patients with Metastatic Genitourinary CancerHeather J Chalfin, Tiziano Pramparo, Amir Mortazavi, et al.Journal of the National Comprehensive Cancer Network : JNCCN|September 4, 2020
NCCN Guidelines Insights: Kidney Cancer, Version 1.2021Robert J Motzer, Eric Jonasch, Shawna Boyle, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 15, 2022
Cabozantinib plus Nivolumab Phase I Expansion Study in Patients with Metastatic Urothelial Carcinoma Refractory to Immune Checkpoint Inhibitor TherapyDaniel M Girardi, Scot A Niglio, Amir Mortazavi, et al.Cancer Discovery|June 1, 2018
Efficacy of BGJ398, a Fibroblast Growth Factor Receptor 1-3 Inhibitor, in Patients with Previously Treated Advanced Urothelial Carcinoma with <i>FGFR3</i> AlterationsSumanta K Pal, Jonathan E Rosenberg, Jean H Hoffman-Censits, et al.Journal of the National Comprehensive Cancer Network : JNCCN|November 7, 2019
NCCN Guidelines Insights: Kidney Cancer, Version 2.2020Robert J Motzer, Eric Jonasch, M Dror Michaelson, et al.Pageof 9